Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment

We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Intensive Care Society 2019-05, Vol.20 (2), p.174-181
Hauptverfasser: Dhokia, VD, Madhavan, D, Austin, A, Morris, Craig G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 181
container_issue 2
container_start_page 174
container_title Journal of the Intensive Care Society
container_volume 20
creator Dhokia, VD
Madhavan, D
Austin, A
Morris, Craig G
description We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.
doi_str_mv 10.1177/1751143718772789
format Article
fullrecord <record><control><sourceid>sage_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6475986</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1751143718772789</sage_id><sourcerecordid>10.1177_1751143718772789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3169-51b4baa852ed254c4683799e0e371178e178a3069136e084ba05390e810b01963</originalsourceid><addsrcrecordid>eNp1UN1KwzAUDqK4MXfvleQFqknTNsmNIMM_GHqjIN6EtD3bMtqmJF1h9z6Jj-aTmDIdKnjgcDh8P-fwIXRKyTmlnF9QnlKaME4F5zEX8gCNY5LyiGXk5RCNBzga8BGaer8moTLKMiGO0YhREnQ0HqPXB9tDhTcesF3g2baz3rr84-0drzTUugxb2xnb4M7i1tnelIBzY4sV1KbQFS5s0zlbYdPgyvTgsKlbbVwNTXeCjha68jD9mhP0fHP9NLuL5o-397OreVQwmskopXmSay3SGMo4TYokE4xLCQSGF7mA0JqRTIbngYjAJSmTBAQlOaEyYxN0ufNtN3kNZRFOO12p1plau62y2qjfSGNWaml7lSU8lWIwIDuDwlnvHSz2WkrUELX6G3WQnP28uRd8BxsI0Y7g9RLU2m5cEzL43_AT62aH7w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment</title><source>PubMed Central(OpenAccess)</source><source>Sage Journals</source><source>EZB Electronic Journals Library</source><creator>Dhokia, VD ; Madhavan, D ; Austin, A ; Morris, Craig G</creator><creatorcontrib>Dhokia, VD ; Madhavan, D ; Austin, A ; Morris, Craig G</creatorcontrib><description>We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.</description><identifier>ISSN: 1751-1437</identifier><identifier>EISSN: 2057-360X</identifier><identifier>DOI: 10.1177/1751143718772789</identifier><identifier>PMID: 31037112</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Case Reports</subject><ispartof>Journal of the Intensive Care Society, 2019-05, Vol.20 (2), p.174-181</ispartof><rights>The Intensive Care Society 2018</rights><rights>The Intensive Care Society 2018 2018 The Intensive Care Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3169-51b4baa852ed254c4683799e0e371178e178a3069136e084ba05390e810b01963</citedby><cites>FETCH-LOGICAL-c3169-51b4baa852ed254c4683799e0e371178e178a3069136e084ba05390e810b01963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475986/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475986/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,21819,27924,27925,43621,43622,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31037112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dhokia, VD</creatorcontrib><creatorcontrib>Madhavan, D</creatorcontrib><creatorcontrib>Austin, A</creatorcontrib><creatorcontrib>Morris, Craig G</creatorcontrib><title>Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment</title><title>Journal of the Intensive Care Society</title><addtitle>J Intensive Care Soc</addtitle><description>We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.</description><subject>Case Reports</subject><issn>1751-1437</issn><issn>2057-360X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1UN1KwzAUDqK4MXfvleQFqknTNsmNIMM_GHqjIN6EtD3bMtqmJF1h9z6Jj-aTmDIdKnjgcDh8P-fwIXRKyTmlnF9QnlKaME4F5zEX8gCNY5LyiGXk5RCNBzga8BGaer8moTLKMiGO0YhREnQ0HqPXB9tDhTcesF3g2baz3rr84-0drzTUugxb2xnb4M7i1tnelIBzY4sV1KbQFS5s0zlbYdPgyvTgsKlbbVwNTXeCjha68jD9mhP0fHP9NLuL5o-397OreVQwmskopXmSay3SGMo4TYokE4xLCQSGF7mA0JqRTIbngYjAJSmTBAQlOaEyYxN0ufNtN3kNZRFOO12p1plau62y2qjfSGNWaml7lSU8lWIwIDuDwlnvHSz2WkrUELX6G3WQnP28uRd8BxsI0Y7g9RLU2m5cEzL43_AT62aH7w</recordid><startdate>20190501</startdate><enddate>20190501</enddate><creator>Dhokia, VD</creator><creator>Madhavan, D</creator><creator>Austin, A</creator><creator>Morris, Craig G</creator><general>SAGE Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190501</creationdate><title>Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment</title><author>Dhokia, VD ; Madhavan, D ; Austin, A ; Morris, Craig G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3169-51b4baa852ed254c4683799e0e371178e178a3069136e084ba05390e810b01963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Case Reports</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dhokia, VD</creatorcontrib><creatorcontrib>Madhavan, D</creatorcontrib><creatorcontrib>Austin, A</creatorcontrib><creatorcontrib>Morris, Craig G</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the Intensive Care Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dhokia, VD</au><au>Madhavan, D</au><au>Austin, A</au><au>Morris, Craig G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment</atitle><jtitle>Journal of the Intensive Care Society</jtitle><addtitle>J Intensive Care Soc</addtitle><date>2019-05-01</date><risdate>2019</risdate><volume>20</volume><issue>2</issue><spage>174</spage><epage>181</epage><pages>174-181</pages><issn>1751-1437</issn><eissn>2057-360X</eissn><abstract>We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>31037112</pmid><doi>10.1177/1751143718772789</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1751-1437
ispartof Journal of the Intensive Care Society, 2019-05, Vol.20 (2), p.174-181
issn 1751-1437
2057-360X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6475986
source PubMed Central(OpenAccess); Sage Journals; EZB Electronic Journals Library
subjects Case Reports
title Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T21%3A27%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20use%20of%20Cytosorb%E2%84%A2%20haemadsorption%20to%20provide%20biochemical%20control%20in%20liver%20impairment&rft.jtitle=Journal%20of%20the%20Intensive%20Care%20Society&rft.au=Dhokia,%20VD&rft.date=2019-05-01&rft.volume=20&rft.issue=2&rft.spage=174&rft.epage=181&rft.pages=174-181&rft.issn=1751-1437&rft.eissn=2057-360X&rft_id=info:doi/10.1177/1751143718772789&rft_dat=%3Csage_pubme%3E10.1177_1751143718772789%3C/sage_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31037112&rft_sage_id=10.1177_1751143718772789&rfr_iscdi=true